Tumas V - Search Results

1

Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases.

Marchioni C, de Souza ID, Acquaro VR Junior, de Souza Crippa JA, Tumas V, Queiroz MEC. Marchioni C, et al. Among authors: tumas v. Anal Chim Acta. 2018 Dec 31;1044:12-28. doi: 10.1016/j.aca.2018.06.016. Epub 2018 Jun 9. Anal Chim Acta. 2018. PMID: 30442393 Review.

2

A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples.

Marchioni C, de Souza ID, Grecco CF, Crippa JA, Tumas V, Queiroz MEC. Marchioni C, et al. Among authors: tumas v. Anal Bioanal Chem. 2017 May;409(14):3587-3596. doi: 10.1007/s00216-017-0300-3. Epub 2017 Mar 23. Anal Bioanal Chem. 2017. PMID: 28337517

3

Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias.

Marchioni C, Santos-Lobato BL, Queiroz MEC, Crippa JAS, Tumas V. Marchioni C, et al. Among authors: tumas v. J Neural Transm (Vienna). 2020 Oct;127(10):1359-1367. doi: 10.1007/s00702-020-02240-9. Epub 2020 Aug 14. J Neural Transm (Vienna). 2020. PMID: 32797288

4

Circulating Endocannabinoids in Huntington's Disease: An Exploratory Cross-Sectional Study.

Manzke P, Crippa JAS, Marchioni C, Queiroz MEC, Brito MCM, Pimentel AV, Bosaipo NB, Foss MP, Tumas V. Manzke P, et al. Among authors: tumas v. J Huntingtons Dis. 2022;11(1):91-95. doi: 10.3233/JHD-210507. J Huntingtons Dis. 2022. PMID: 35124656

5

Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation.

Santos-Lobato BL, Gardinassi LG, Bortolanza M, Peti APF, Pimentel ÂV, Faccioli LH, Del-Bel EA, Tumas V. Santos-Lobato BL, et al. Among authors: tumas v. Mol Neurobiol. 2022 Feb;59(2):1140-1150. doi: 10.1007/s12035-021-02625-1. Epub 2021 Dec 2. Mol Neurobiol. 2022. PMID: 34855116

6

Bipolar disorder, a precursor of Parkinson's disease?

Novaretti TMS, Novaretti N, Tumas V. Novaretti TMS, et al. Among authors: tumas v. Dement Neuropsychol. 2016 Oct-Dec;10(4):361-364. doi: 10.1590/s1980-5764-2016dn1004018. Dement Neuropsychol. 2016. PMID: 29213483 Free PMC article.

7

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Crippa JAS, et al. Among authors: tumas v. Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):121-133. doi: 10.1007/s00406-019-00982-6. Epub 2019 Jan 31. Eur Arch Psychiatry Clin Neurosci. 2019. PMID: 30706171 Review.

8

The accuracy of diagnosis of major depression in patients with Parkinson's disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory.

Tumas V, Rodrigues GG, Farias TL, Crippa JA. Tumas V, et al. Arq Neuropsiquiatr. 2008 Jun;66(2A):152-6. doi: 10.1590/s0004-282x2008000200002. Arq Neuropsiquiatr. 2008. PMID: 18545773 Free article.

9

Cannabidiol for the treatment of psychosis in Parkinson's disease.

Zuardi AW, Crippa JA, Hallak JE, Pinto JP, Chagas MH, Rodrigues GG, Dursun SM, Tumas V. Zuardi AW, et al. Among authors: tumas v. J Psychopharmacol. 2009 Nov;23(8):979-83. doi: 10.1177/0269881108096519. Epub 2008 Sep 18. J Psychopharmacol. 2009. PMID: 18801821

10

Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.

Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA. Padovan-Neto FE, et al. Among authors: tumas v. Neuroscience. 2009 Mar 31;159(3):927-35. doi: 10.1016/j.neuroscience.2009.01.034. Epub 2009 Jan 23. Neuroscience. 2009. PMID: 19302833

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

138 results

Search Page